Links to publications that used this kit:
Derosa G, Cicero AF, Franzetti IG, et al. Effects of exenatide + metformin combination on some adipocytokines levels: A comparison with metformin monotherapy.
Can. J. Physiol. Pharmacol. 2013. doi:10.1139/cjpp-2012-0300.
Rotkegel S, Chudek J, Spiechowicz-zaton U, Ficek R, Adamczak M, Wiecek A. The Effect of Sodium Restricted Diet on Plasma Visfatin Levels in Hypertensive Patients with Visceral Obesity.
Kidney Blood Press Res. 2013;37(2-3):124-131.
Derosa G, Ragonesi PD, Carbone A, et al. Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients.
Pharmacol Res. 2013. doi:10.1016/j.phrs.2013.04.005
Caron-Cantin SM, Martin J, Bastien M, et al. Acute and Chronic Effects of Biliopancreatic Diversion with Duodenal Switch Surgery on Plasma Visfatin and Apelin Levels in Patients with Severe Obesity.
Obes Surg. 2013; 10.1007/s11695-013-0952-9
Mahmood N et al. Association of visfatin with chronic kidney disease in a cohort of patients with and without diabetes.
J Pak Med Assoc. 2010 Nov;60(11):922-6.
Wang et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide.
Cardiovasc Res. 2009 Feb 1;81(2):370-80.
Skokowa et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway.
Nat Med. 2009 Feb;15(2):151-8.
de Boer et al. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
Am J Physiol Gastrointest Liver Physiol. 2009 Feb;296(2):G196-201.
du Luis et al. Relation of visfatin to cardiovascular risk factors and adipocytokines in patients with impaired fasting glucose.
Nutrition. 2009 Jan 6. [Epub ahead of print]
Li et al. The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo.
Cytokine. 2009 Jan;45(1):12-9.
Kato et al. Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients.
Am J Nephrol. 2009;29(1):31-5.
Zhong et al. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis.
Clin Endocrinol (Oxf). 2008 Dec;69(6):878-84.
Retnakaran et al. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study.
Clin Endocrinol (Oxf). 2008 Dec;69(6):885-93.
Younossi et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).
Obes Surg. 2008 Nov;18(11):1430-7.
Storka et al. Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
Eur J Clin Invest. 2008 Nov;38(11):820-6.
Panidis et al. Plasma visfatin levels in normal weight women with polycystic ovary syndrome.
Eur J Intern Med. 2008 Oct;19(6):406-12.
Dahmen et al. Elevated peripheral visfatin levels in narcoleptic patients.
PLoS ONE. 2008 Aug 20;3(8):e2980.
Botella-Carretero et al. The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery.
Obes Surg. 2008 Aug;18(8):1000-6.
Brema et al. Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus.
Diabetes Obes Metab. 2008 Jul;10(7):600-2.
Palin et al. Visfatin expression is not associated with adipose tissue abundance in the porcine model.
Domest Anim Endocrinol. 2008 Jul;35(1):58-73.
Ibáñez et al. Gender specificity of body adiposity and circulating adiponectin, visfatin, insulin, and insulin growth factor-I at term birth: relation to prenatal growth.
J Clin Endocrinol Metab. 2008 Jul;93(7):2774-8.
Perez-Iglesias et al. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
J Clin Psychopharmacol. 2008 Jun;28(3):289-95.
de Luis et al. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients.
Nutrition. 2008 Jun;24(6):517-21.
Ibáñez et al. Visceral adiposity without overweight in children born small for gestational age.
J Clin Endocrinol Metab. 2008 Jun;93(6):2079-83.
Yilmaz et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin.
Nephrol Dial Transplant. 2008 May;23(5):1621-7.
Bouhours-Nouet et al. High birth weight and early postnatal weight gain protect obese children and adolescents from truncal adiposity and insulin resistance: metabolically healthy but obese subjects?
Diabetes Care. 2008 May;31(5):1031-6.
Krzysik-Walker et al. Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens.
Endocrinology. 2008 Apr;149(4):1543-50.
Matsui et al. Visfatin (pre-B cell colony-enhancing factor) gene expression in patients with rheumatoid arthritis.
Ann Rheum Dis. 2008 Apr;67(4):571-2.
Jarrar et al. Adipokines and cytokines in non-alcoholic fatty liver disease.
Aliment Pharmacol Ther. 2008 Mar 1;27(5):412-21.
Yilmaz et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.
Nephrol Dial Transplant. 2008 Mar;23(3):959-65.
Kendal-Wright et al. Chronic stretching of amniotic epithelial cells increases pre-B cell colony-enhancing factor (PBEF/visfatin) expression and protects them from apoptosis.
Placenta. 2008 Mar;29(3):255-65.
Rauchenzauner et al. Adiponectin and visfatin concentrations in children treated with valproic acid.
Epilepsia. 2008 Feb;49(2):353-7.
Choi et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease.
Eur J Endocrinol. 2008 Feb;158(2):203-7.
Peng et al. Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men.
Clin Chim Acta. 2008 Jan;387(1-2):31-5.
Kostapanos et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.
Eur J Pharmacol. 2008 Jan 14;578(2-3):249-52.
Filippatos et al. Increased plasma visfatin levels in subjects with the metabolic syndrome.
Eur J Clin Invest. 2008 Jan;38(1):71-2.
López-Bermejo et al. Cord serum visfatin at term birth: maternal smoking unmasks the relation to foetal growth.
Clin Endocrinol (Oxf). 2008 Jan;68(1):77-81.
Seo et al. Plasma visfatin levels are positively associated with circulating interleukin-6 in apparently healthy Korean women.
Diabetes Res Clin Pract. 2008 Jan;79(1):108-11.
Mazaki-Tovi et al. Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition.
J Perinat Med. 2008;36(6):485-96.
Goldfine et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal.
J Clin Endocrinol Metab. 2007 Dec;92(12):4678-85.
Körner et al. Molecular characteristics of serum visfatin and differential detection by immunoassays.
J Clin Endocrinol Metab. 2007 Dec;92(12):4783-91.
Shea et al. Serum retinol-binding protein 4 concentrations in response to short-term overfeeding in normal-weight, overweight, and obese men.
Am J Clin Nutr. 2007 Nov;86(5):1310-5.
Oki et al. Circulating visfatin level is correlated with inflammation, but not with insulin resistance.
Clin Endocrinol (Oxf). 2007 Nov;67(5):796-800.
Garcia-Fuentes et al. Plasma Visfatin Concentrations in Severely Obese Subjects Are Increased After Intestinal Bypass
Obesity (Silver Spring). 2007 Oct;15(10):2391-5.
Choi et al. Effect of exercise training on plasma visfatin and eotaxin levels.
Eur J Endocrinol. 2007 Oct;157(4):437-42.
Wang et al. The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile.
Pflugers Arch. 2007 Sep;454(6):971-6.
Chen et al. The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women
Metabolism. 2007 Sep;56(9):1216-20.
Brentano et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.
Arthritis Rheum. 2007 Sep;56(9):2829-39.
Zahorska-Markiewicz et al. Serum concentration of visfatin in obese women.
Metabolism. 2007 Aug;56(8):1131-4.
Hsieh et al. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus.
Metabolism. 2007 Aug;56(8):1087-92.
Nüsken et al. Preanalytical influences on the measurement of visfatin by enzyme immuno assay.
Clin Chim Acta. 2007 Jul;382(1-2):154-6.
Haider et al. Visfatin response to glucose is reduced in women with gestational diabetes mellitus.
Diabetes Care. 2007 Jul;30(7):1889-91.
Malamitsi-Puchner et al. Perinatal circulating visfatin levels in intrauterine growth restriction.
Pediatrics. 2007 Jun;119(6):e1314-8.
Zhou et al. Tigogenin inhibits adipocytic differentiation and induces osteoblastic differentiation in mouse bone marrow stromal cells.
Mol Cell Endocrinol. 2007 May 30;270(1-2):17-22.
Ingelsson et al. Clinical correlates of circulating visfatin levels in a community-based sample.
Diabetes Care. 2007 May;30(5):1278-80.
Lewandowski et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance.
Diabetologia. 2007 May;50(5):1033-7.
Haider et al. Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.
Clin Pharmacol Ther. 2007 Apr;81(4):580-5.
Malamitsi-Puchner et al. Blood visfatin concentrations in normal full-term pregnancies.
Acta Paediatr. 2007 Apr;96(4):526-9.
Sandeep et al. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians.
Metabolism. 2007 Apr;56(4):565-70.
Takebayashi et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus.
Metabolism. 2007 Apr;56(4):451-8.
Dogru et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.
Diabetes Res Clin Pract. 2007 Apr;76(1):24-9.
Fernández-Real et al. Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance.
Diabetes Care. 2007 Mar;30(3):616-21.
Dogru et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension.
J Hum Hypertens. 2007 Feb;21(2):173-5.
Zhou et al. Macrostemonoside A promotes visfatin expression in 3T3-L1 cells.
Biol Pharm Bull. 2007 Feb;30(2):279-83.
Manco et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women.
J Clin Endocrinol Metab. 2007 Feb;92(2):483-90.
Dahl et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization.
Circulation. 2007 Feb 27;115(8):972-80.
Sun et al. Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men.
Am J Clin Nutr. 2007 Feb;85(2):399-404.
Varma et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
J Clin Endocrinol Metab. 2007 Feb;92(2):666-72.
Moschen et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.
J Immunol. 2007 Feb 1;178(3):1748-58.
Frydelund-Larsen et al. Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise.
Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E24-31.
Yonezawa et al. Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway.
FEBS Lett. 2006 Dec 11;580(28-29):6635-43.
Dimitriadis et al. Insulin action in adipose tissue and muscle in hypothyroidism.
J Clin Endocrinol Metab. 2006 Dec;91(12):4930-7.
Tan et al. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin.
J Clin Endocrinol Metab. 2006 Dec;91(12):5022-8.
Krzyzanowska et al. Increase in visfatin after weight loss induced by gastroplastic surgery.
Obesity (Silver Spring). 2006 Nov;14(11):1886-9.
Haider et al. Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.
J Clin Endocrinol Metab. 2006 Nov;91(11):4702-4.
Haider et al. Free fatty acids normalize a rosiglitazone-induced visfatin release.
Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E885-90.
López-Bermejo et al. Serum visfatin increases with progressive beta-cell deterioration.
Diabetes. 2006 Oct;55(10):2871-5.
Haider et al. The adipokine visfatin is markedly elevated in obese children.
J Pediatr Gastroenterol Nutr. 2006 Oct;43(4):548-9.
Otero et al. Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.
Ann Rheum Dis. 2006 Sep;65(9):1198-201.
Jian et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.
Diabet Med. 2006 Sep;23(9):967-73.
Schindler et al. Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects.
Eur J Clin Invest. 2006 Sep;36(9):640-6.
Haider et al. The release of the adipocytokine visfatin is regulated by glucose and insulin.
Diabetologia. 2006 Aug;49(8):1909-14.
Pagano et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans.
J Clin Endocrinol Metab. 2006 Aug;91(8):3165-70.
Nowell et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.
Arthritis Rheum. 2006 Jul;54(7):2084-95.
Böttcher et al. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans.
J Clin Endocrinol Metab. 2006 Jul;91(7):2725-31.
Krzyzanowska et al. Increased visfatin concentrations in women with gestational diabetes mellitus.
Clin Sci (Lond). 2006 May;110(5):605-9.
Haider et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.
J Clin Endocrinol Metab. 2006 Apr;91(4):1578-81.
Curat et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin.
Diabetologia. 2006 Apr;49(4):744-7.
Hammarstedt et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones.
J Clin Endocrinol Metab. 2006 Mar;91(3):1181-4.
Chen et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.
J Clin Endocrinol Metab. 2006 Jan;91(1):295-9.
Berndt et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.
Diabetes. 2005 Oct;54(10):2911-6.
Chan et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism.
Clin Chem. 2005 Mar;51(3):578-85.
Chen MP, et al. J Clin Endocrin Metab. First pub: 10/18/05 as doi:10.1210/jc2005-1475
